Learning Objectives
Differentiate between the various interleukin (IL) inhibitors used in the management of moderate-to-severe plaque psoriasis and psoriatic arthritis. Master the specific cytokine targetsโIL-12, IL-17, and IL-23โand understand the biological rationale for their clinical application.
1. IL-17 Pathway Inhibitors
IL-17 is a key pro-inflammatory cytokine produced by Th17 cells that drives keratinocyte proliferation and neutrophil recruitment in psoriasis. These drugs either neutralize the cytokine itself or block its receptor.
| Drug Name | Specific Target | Mechanism / Clinical Pearl |
|---|---|---|
| Ixekizumab | IL-17A | Monoclonal antibody; neutralizes the IL-17A cytokine. |
| Secukinumab | IL-17A | High efficacy in both skin clearance and psoriatic arthritis. |
| Brodalumab | IL-17 Receptor (IL-17RA) | Blocks the receptor directly; associated with a boxed warning for suicidal ideation/behavior. |
2. IL-23 and IL-12/23 Inhibitors
IL-23 is critical for the maintenance and survival of Th17 cells. Some biologics target the p40 subunit shared by IL-12 and IL-23, while newer agents specifically target the p19 subunit of IL-23 alone.
| Drug Name | Specific Target | Clinical Context |
|---|---|---|
| Ustekinumab | IL-12 and IL-23 (p40 subunit) | Classic biologic used for both Psoriasis and Crohnโs disease. |
| Guselkumab | IL-23 (p19 subunit) | Specific IL-23 inhibition minimizes interference with IL-12/Th1 pathways. |
| Risankizumab | IL-23 (p19 subunit) | Known for infrequent maintenance dosing (every 12 weeks). |
| Tildrakizumab | IL-23 (p19 subunit) | Specific p19 inhibitor for moderate-to-severe plaque psoriasis. |
3. Safety and Monitoring
Similar to TNF-ฮฑ inhibitors, these biologics require pre-treatment screening for latent infections. However, their risk profiles differ slightly.
| Drug Class | Common Adverse Effects / Risks |
|---|---|
| IL-17 Inhibitors | Increased risk of Candida infections (IL-17 is vital for fungal mucosal immunity). May exacerbate IBD. |
| IL-23 Inhibitors | Upper respiratory infections, tinea infections, and injection site reactions. |
| General Monitoring | Screening for Tuberculosis (TB) is required for all these agents before initiation. |
Activity
High-Yield Mnemonics & Tips:
- Ustekinumab: Think “U” for Unitโit targets the p40 unit shared by both 12 and 23.
- IL-17 and Fungi: If a patient on Secukinumab develops oral thrush, it is a direct consequence of the drug’s mechanism (IL-17 deficiency = fungal susceptibility).
- The “mabs”: -umab indicates a fully human monoclonal antibody, while -ximab indicates a chimeric antibody (increased risk of infusion reactions/neutralizing antibodies).